| __timestamp | Halozyme Therapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 59644696 |
| Thursday, January 1, 2015 | 40028000 | 79541000 |
| Friday, January 1, 2016 | 45853000 | 98015000 |
| Sunday, January 1, 2017 | 53816000 | 103958000 |
| Monday, January 1, 2018 | 60804000 | 103654000 |
| Tuesday, January 1, 2019 | 77252000 | 128951000 |
| Wednesday, January 1, 2020 | 45736000 | 135799000 |
| Friday, January 1, 2021 | 50323000 | 149883000 |
| Saturday, January 1, 2022 | 143526000 | 220206000 |
| Sunday, January 1, 2023 | 149182000 | 265542000 |
| Monday, January 1, 2024 | 154335000 |
Unleashing insights
In the dynamic world of biotechnology, operational efficiency is key to sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Halozyme Therapeutics, Inc. and Travere Therapeutics, Inc., from 2014 to 2023. Over this period, Travere Therapeutics consistently outpaced Halozyme in SG&A spending, with a notable 95% increase from 2014 to 2023. In contrast, Halozyme's expenses grew by approximately 315%, reflecting strategic investments in operational capabilities. The year 2022 marked a significant surge for both companies, with Halozyme's expenses peaking at 143 million, a 215% increase from 2014, while Travere reached 220 million, a 270% rise. This trend underscores the escalating costs associated with maintaining competitive advantage in the biotech sector. As these companies continue to innovate, understanding their financial strategies offers valuable insights into their market positioning.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing SG&A Expenses: Alkermes plc vs Travere Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Travere Therapeutics, Inc. and Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.